FDA to re­lease list of sur­ro­gate end­points in on­col­o­gy

Scott Got­tlieb, FDA Com­mis­sion­er, said Mon­day at the Na­tion­al Press Club in Wash­ing­ton, DC that his agency will re­lease a list of sur­ro­gate end­points used in can­cer drug de­vel­op­ment soon.

His speech touched on four top­ics — in­clud­ing mod­ern­iz­ing the tri­al process and en­abling pay­ers to lever­age more open ac­cess to re­al world da­ta. “In the com­ing weeks, for the first time, CDER will pub­lish on the web, a list of the sur­ro­gate end­points that were the pri­ma­ry ba­sis of ap­proval or li­cen­sure of a drug or bi­o­log­i­cal for both ac­cel­er­at­ed and tra­di­tion­al ap­provals,” he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER